Shopping Cart
- Remove All
Your shopping cart is currently empty
PF-06478939 TFA
Catalog No. T79174
PF-06478939 TFA is a peptide that acts as a non-brain-penetrating agonist at the oxytocin (OT) and vasopressin receptors, exhibiting EC50 values of 0.01 nM and 0.078 nM, respectively [1].
PF-06478939 TFA
PF-06478939 TFA
Catalog No. T79174
PF-06478939 TFA is a peptide that acts as a non-brain-penetrating agonist at the oxytocin (OT) and vasopressin receptors, exhibiting EC50 values of 0.01 nM and 0.078 nM, respectively [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | Backorder | |
| 50 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PF-06478939 TFA"
Oxytocin acetate
α-Hypophamine acetate, Oxytocin acetate (50-56-6 free base), Oxytocic hormone acetate
T51456233-83-6
Oxytocin acetate (α-Hypophamine acetate) is a mammalian neurohypophysial hormone, a ligand of oxytocin receptor.
- $45
Size
QTY
SSR126768A
SSR-126768A, SSR 126768A
T28855785048-28-4In house
SSR126768A is a novel and selective, orally active and potent oxytocin (OT) receptor antagonist with inhibitory effects on uterine contractions for the prevention of preterm labor.
- $350
Size
QTY
LIT-001
T118572245072-21-1
LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.
- $64
Size
QTY
Atosiban acetate
RWJ22164, RW22164, Atosiban acetate (90779-69-4 free base)
T5148914453-95-5
Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
- $67
Size
QTY
L-371,257
T15682162042-44-6
L-371,257 is a competitive antagonist of oxytocin receptor with pA2 of 8.4 and Ki of 19 nM. L-371,257 shows a Ki of 3.7 nM for vasopressin receptor 1a.
- $34
Size
QTY
Carbetocin acetate
Carbetocin acetate(37025-55-1 free base)
T7601L1631754-28-3
Carbetocin acetate is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth.
- $47
Size
QTY
Oxytocin
α-Hypophamine, Oxytocin (Syntocinon), Oxytocic hormone
T502650-56-6
Oxytocin (Syntocinon) is a mammalian neuropituitary hormone, a pleiotropic hypothalamic peptide and ligand for the oxytocin receptor, which contributes to labor, lactation, and pro-social behavior. Oxytocin has the ability to stimulate mammary secretion of breast milk, promote contraction of uterine smooth muscle during labor, and facilitate mothering.
- $40
Size
QTY
Carbetocin
Cited
T760137025-55-1
Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth.
- $540
Size
QTY
CitedPro8-Oxytocin
T8013324327-19-3
Pro8-Oxytocin, a modified oxytocin (OXT) ligand, elicits more potent and efficacious responses at primate OXTR and induces stronger behavioral effects compared to the standard mammalian OXT ligand (Leu8-Oxytocin). It demonstrates lower efficacy than Vasopressin (AVP) at human AVPR1a, yet shows a higher efficacious response at marmoset AVPR1a [1].
- Inquiry Price
Size
QTY
Pro8-Oxytocin TFA
T80134
Pro8-Oxytocin TFA, a modified oxytocin (OXT) ligand, exhibits greater potency and efficacy than the standard mammalian OXT ligand, Leu8-Oxytocin, at primate OXTR and elicits more pronounced behavioral effects. Compared to vasopressin (AVP), Pro8-Oxytocin TFA has a lower efficacious response at human AVPR1a, yet shows a higher efficacy at the marmoset AVPR1a [1].
- Inquiry Price
Size
QTY
(Val3,Pro8)-Oxytocin
T801402134138-89-7
(Val3,Pro8)-Oxytocin functions primarily as a Gq-dependent pathway agonist and exhibits secondary activity as a reduced efficacy agonist for β-arrestin recruitment and receptor-mediated endocytosis at the oxytocin receptor (OXTR) [1].
- Inquiry Price
Size
QTY
PF-06655075 TFA
T81501
PF-06655075 (TFA) is the trifluoroacetic acid (TFA) salt of PF-06655075, a novel non-brain-penetrant oxytocin receptor agonist with enhanced selectivity for the oxytocin receptor and improved pharmacokinetic stability. It serves as a valuable tool compound for investigating the influence of peripheral oxytocin on behavioral responses [1].
- Inquiry Price
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | PF-06478939 TFA is a peptide that acts as a non-brain-penetrating agonist at the oxytocin (OT) and vasopressin receptors, exhibiting EC50 values of 0.01 nM and 0.078 nM, respectively [1]. |
| Formula | C78H134N14O22S2.xC2HF3O2 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PF-06478939 TFA | purchase PF-06478939 TFA | PF-06478939 TFA cost | order PF-06478939 TFA | PF-06478939 TFA formula
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.